Previous 10 | Next 10 |
2024-01-31 03:09:25 ET Summary Arcutis is a late-stage biopharmaceutical company focused on developing treatments for immune-mediated dermatological diseases. The company has received FDA approval for its topical cream, Zoryve, for the treatment of plaque psoriasis and seborrheic ...
Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE ® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older WESTLAKE VILLAGE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ar...
2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus, ( EOLS ) +2% . SSR Mining ( SSRM ) +2% . Losers: Progress Software ...
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itch Seborrheic dermatitis affects mo...
New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicle ZORYVE foam provided rapid and significant improvement in qu...
Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved measurable improvement by Week 1 (the earliest timepoint measured) Data presented at the 2024 W...
2024-01-03 16:34:46 ET Gainers: iHeartMedia ( IHRT ) +10% . Arcutis Biotherapeutics ( ARQT ) +8% . Cipher Mining ( CIFR ) +7% . Pacira BioSciences ( PCRX ) +6% . Argo Blockchain ( ARBK ) +6% . Losers: Cal-Main...
2024-01-03 10:25:39 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...
2024-01-03 05:29:44 ET Related stock stories: SoFi Technologies: Rapid Growth Might Be Worth The Risk Masonite And PGT Innovations: Slamming The Door Following A Big And Expensive Deal SoFi Technologies: Time To Load Up Bloomin’ Brands appoints Dave Ge...
2024-01-02 16:55:53 ET Gainers: Bloomin' Brands ( BLMN ) +6% . Arcutis Biotherapeutics ( ARQT ) +6% . Stronghold Digital Mining ( SDIG ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Guardant Health ( GH ) +3% . Losers: ...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...